These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 16489046)

  • 1. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
    Zhang H; Pelzer AM; Kiang DT; Yee D
    Cancer Res; 2007 Jan; 67(1):391-7. PubMed ID: 17210722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of antibody-mediated insulin-like growth factor I receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells.
    Ohtani M; Numazaki M; Yajima Y; Fujita-Yamaguchi Y
    Biosci Trends; 2009 Aug; 3(4):131-8. PubMed ID: 20103837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.
    Ye JJ; Liang SJ; Guo N; Li SL; Wu AM; Giannini S; Sachdev D; Yee D; Brünner N; Ikle D; Fujita-Yamaguchi Y
    Horm Metab Res; 2003; 35(11-12):836-42. PubMed ID: 14710366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
    Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
    Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells.
    Zhang H; Sachdev D; Wang C; Hubel A; Gaillard-Kelly M; Yee D
    Breast Cancer Res Treat; 2009 Mar; 114(2):277-85. PubMed ID: 18418709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling.
    Pandini G; Vigneri R; Costantino A; Frasca F; Ippolito A; Fujita-Yamaguchi Y; Siddle K; Goldfine ID; Belfiore A
    Clin Cancer Res; 1999 Jul; 5(7):1935-44. PubMed ID: 10430101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
    Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
    Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors.
    Pandini G; Wurch T; Akla B; Corvaia N; Belfiore A; Goetsch L
    Eur J Cancer; 2007 May; 43(8):1318-27. PubMed ID: 17451939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
    Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
    Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines.
    Nakamura K; Hongo A; Kodama J; Miyagi Y; Yoshinouchi M; Kudo T
    Cancer Res; 2000 Feb; 60(3):760-5. PubMed ID: 10676665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody.
    Kusada Y; Morizono T; Matsumoto-Takasaki A; Sakai K; Sato S; Asanuma H; Takayanagi A; Fujita-Yamaguchi Y
    J Biochem; 2008 Jan; 143(1):9-19. PubMed ID: 17956902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation.
    Jackson-Booth PG; Terry C; Lackey B; Lopaczynska M; Nissley P
    Horm Metab Res; 2003; 35(11-12):850-6. PubMed ID: 14710368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.